Patent ID: 11913078
Assignee: MYRIAD INTERNATIONAL GMBH
Field: Biotechnology (Chemistry)
Classification: CPC C | IPC C

Claim 0:
1. A method for treating a patient having an estrogen receptor positive and HER2 negative breast tumor, the method comprising:
determining whether the patient will benefit from cytotoxic chemotherapy by:
(1) determining in a sample from the tumor the RNA expression level values of a set of marker genes, the set of marker genes comprising AURKA and at least two of the following genes: BIRC5, PVALB, NMU, STC2, RBBP8, PTGER3, CXCL12, CDH1, and PIP;
(2) combining the expression level values determined in step (1) to yield a test combined score; and

administering a treatment regimen comprising a cytotoxic chemotherapy to the patient if the test combined score exceeds a reference combined score, or
administering a treatment regimen comprising a non-cytotoxic therapy to the patient if the test combined score does not exceed the reference combined score.